When evaluating individual components of the composite outcome, both oral corticosteroid use (adjusted IRR: 0.54, 95% CI: 0.41–0.70) and IBD-related hospitalization (adjusted IRR: 0.73, 95% CI: 0.58–0.91) were significantly lower amongst GLP-1 RA/DPP-4 inhibitor users. Here, DPP4 is linked to inflammatory bowel disease.